

Australia Minimally Invasive Biopsy Techniques Market Assessment, By Product Offered [Tests, Kits & Consumables, Instruments], By Technique [Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others], By Circulating Biomarker [Circulating Tumor Cells, Cell Free DNA, Circulating Tumor DNA, Extracellular Vesicles, Others], By Application [Clinical, Therapeutic], By End-user [Hospitals & Clinics, Academic & Research Institutions, Ambulatory Care Centers], By Region, Opportunities and Forecast, 2016-2030F

Market Report | 2024-04-19 | 105 pages | Market Xcel - Markets and Data

AVAILABLE LICENSES:

- Single User License \$3300.00
- Multi-User/Corporate Licence \$4500.00
- Custom Research License \$7000.00

Report description:

Australia minimally invasive biopsy techniques market size was valued at USD 98.7 million in 2022, which is expected to reach USD 180 million in 2030, with a CAGR of 7.8% for the forecast period between 2023 and 2030F. The Australia minimally invasive biopsy techniques market has grown notably due to several key factors. With advancements in medical technology and increased awareness, there has been a growing preference for minimally invasive biopsy techniques among both patients and healthcare providers. These techniques offer reduced discomfort, shorter recovery times, and fewer complications compared to traditional invasive procedures. Additionally, the demand for early and accurate cancer diagnosis has driven the market, leading to the development of innovative biopsy technologies that provide precise results while minimizing patient inconvenience. Recent research in the field has been transformative, with significant emphasis on improving the accuracy and efficiency of biopsy procedures. Researchers at the University of Technology Sydney (UTS) have introduced a groundbreaking tool capable of detecting and analyzing cancer cells in blood samples. The innovation addresses patient concerns and enables medical professionals to monitor treatment progress closely, leading to better outcomes. Such advancements, along with the integration

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

of AI-driven diagnostics and personalized medicine, are poised to revolutionize the Australia further minimally invasive biopsy techniques market, enhancing patient care, and contributing to the overall growth of the healthcare sector in the country. For example, in 2023, a pioneering achievement has emerged from the University of Technology Sydney (UTS), where researchers have devised a groundbreaking instrument capable of discerning and analyzing cancer cells in blood samples. The milestone offers a means for medical practitioners to circumvent the need for intrusive biopsy surgeries and provides a mechanism to monitor the progress of treatments. The innovation, known as the Static Droplet Microfluidic device, exhibits remarkable proficiency in swiftly detecting circulating tumor cells that have disseminated from a primary tumor and infiltrated the bloodstream. The device operates by leveraging a distinctive metabolic signature specific to cancer cells, enabling the differentiation of these cells from normal blood cells.

Growing Preference for Minimally Invasive Procedures

The Australia minimally invasive biopsy techniques market is witnessing a notable surge due to the preference for minimally invasive procedures. The trend is fueled by several factors, including advancements in medical technology, a growing emphasis on patient comfort, and the desire to reduce post-procedural recovery time. Both medical professionals and patients increasingly prefer minimally invasive biopsy techniques due to their reduced invasiveness, lower risk of complications, and quicker recovery compared to traditional invasive procedures. The prospect of avoiding the discomfort and longer hospital stays associated with conventional biopsies has led to a significant shift towards these less invasive alternatives.

The preference aligns with the broader global trend of embracing minimally invasive approaches in healthcare, offering improved diagnostic capabilities, and contributing to enhanced patient outcomes. For instance, as per the report released by AIHW in October 2022, there were roughly 162,163 newly diagnosed cancer cases in 2022, marking an increase from the 158,530 cases identified in 2021. The demand for minimally invasive surgeries is on the rise, driven by the advantages they offer to patients, including reduced postoperative discomfort, fewer complications during and after the procedure, shorter hospitalization periods, quicker recovery timelines, minimized impact on the immune system, and smaller incisions. This growing demand for minimally invasive techniques is particularly prominent in the treatment of cancer and other chronic diseases linked to lifestyle factors.

Rising Incidence of Cancer

Australia minimally invasive biopsy techniques market is witnessing a notable increase in demand due to the rising incidence of cancer across the country. As reported by various healthcare authorities, there has been a concerning upward trend in the number of cancer cases diagnosed in recent years. This surge in cancer incidence has fueled the need for more effective and less invasive diagnostic and treatment options. Minimally invasive biopsy techniques are becoming increasingly crucial in addressing the growing healthcare challenges. These techniques offer numerous benefits, such as reduced patient discomfort, lower risk of complications, quicker recovery times, and a potential to lower stress on the immune system. As a result, the market for minimally invasive biopsy techniques is expanding in response to the urgent need for improved cancer diagnosis and treatment strategies.

Advancement in Technology for Market Growth

The advancements in technology has been a significant driver of market growth for the Australia minimally invasive biopsy techniques market. The development of advanced imaging techniques such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) has enabled the use of more precise and efficient biopsy devices, leading to higher accuracy and safety of the procedures. Furthermore, the integration of artificial intelligence (AI) in imaging and biopsy devices has enabled the real-time analysis of tissue samples, allowing for more accurate diagnosis and treatment planning. Additionally, the use of robotics and other automation technologies has led to the development of robotic-assisted biopsy devices, allowing for more precise and controlled biopsy procedures.

These technological advancements have resulted in a higher adoption rate among healthcare providers and increased patient confidence in the safety and efficacy of minimally invasive biopsy techniques. As the technology continue to evolve, it is expected to drive further growth in the Australia minimally invasive biopsy techniques market. For example, in 2022, Boston Scientific Corporation announced its definitive agreement to acquire Apollo Endosurgery, Inc. for a cash valuation of USD 10 per share, which translated to an enterprise value totaling around USD 615 million.

Apollo Endosurgery's product range comprises devices specifically designed for endoluminal surgery (ELS) procedures, aimed at closing gastrointestinal defects, managing gastrointestinal complications, and assisting weight loss in patients dealing with

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

obesity. ELS serves as a less invasive alternative to both open and laparoscopic surgery, offering patients with gastrointestinal tract issues or morbid obesity to quicker recovery and reduced surgical complication risks. This acquisition demonstrates Boston Scientific's strategic intent to expand its capabilities in minimally invasive medical solutions.

Impact of COVID-19

Due to interruptions in healthcare infrastructure and patient behavior modifications, the pandemic substantially influenced the market for minimally invasive biopsy procedures in Australia. The number of biopsy operations decreased because of limits on elective treatments and restricted access to healthcare facilities. Many patients' diagnoses and treatments were delayed because of the pandemic's uncertainty, potentially harming their health. The market became resilient, gradually increasing the demand as healthcare facilities adopted safety practices and adjusted in response to the pandemic. The rising usage of telemedicine and remote consultations has brought on a rise in virtual biopsy procedures. Overall, while the pandemic has posed challenges to the market, it has accelerated the adoption of digital technologies and remote healthcare, which could lead to long-term benefits for the Australia minimally invasive biopsy techniques market.

Key Player Landscape and Outlook

Australia minimally invasive biopsy techniques market features several key players driving innovation and growth in the sector. Companies such as Medtronic plc, Boston Scientific Corporation, Becton Dickinson, and Company, and Hologic, Inc. are prominent players. These companies actively invest in research and development to introduce advanced biopsy devices and technologies, ensuring higher accuracy, reduced invasiveness, and improved patient outcomes. Moreover, strategic collaborations, mergers, and acquisitions have been witnessed in recent years, further intensifying the competition. The market outlook for minimally invasive biopsy techniques in Australia remains optimistic, primarily due to the rising prevalence of cancer and the growing demand for early and accurate diagnoses.

Technological advancements and an aging population are expected to drive continued growth in the sector, fostering a competitive landscape focused on delivering innovative solutions for minimally invasive biopsies. For instance, in 2022, At UNSW Sydney, scientists are currently focused on advancing safer and less invasive methods for conducting tumor biopsies. The research aims to minimize patient discomfort and reduce the risks associated with traditional biopsy procedures. The innovative techniques being developed hold the potential to revolutionize the field of tumor diagnosis, allowing for more precise and effective treatment strategies while enhancing the patient outcomes.

Table of Contents:

1. Research Methodology
2. Project Scope & Definitions
3. Impact of COVID-19 on Australia Minimally Invasive Biopsy Techniques Market
4. Executive Summary
5. Australia Minimally Invasive Biopsy Techniques Market Outlook, 2016-2030F
 - 5.1. Market Size & Forecast
 - 5.1.1. By Value
 - 5.1.2. By Volume
 - 5.2. By Product Offered
 - 5.2.1. Tests
 - 5.2.2. Kits & Consumables
 - 5.2.3. Instruments
 - 5.3. By Technique
 - 5.3.1. Liquid Biopsy
 - 5.3.2. Optical Biopsy
 - 5.3.3. Brush Biopsy
 - 5.3.4. Pigmented Lesion Assays
 - 5.3.5. Others (Breath Biopsy)
 - 5.4. By Circulating Biomarker

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.4.1.□Circulating Tumor Cells (CTCs)
 - 5.4.2.□Cell Free DNA (cfDNA)
 - 5.4.3.□Circulating Tumor DNA (ctDNA)
 - 5.4.4.□Extracellular Vesicles
 - 5.4.5.□Others (miRNA, CTECs, circRNA)
 - 5.5.□ By Application
 - 5.5.1.□Clinical
 - 5.5.1.1.□Treatment Monitoring
 - 5.5.1.2.□Prognosis & Recurrence Monitoring
 - 5.5.1.3.□Treatment Selection
 - 5.5.1.4.□Others (Diagnosis & Screening)
 - 5.5.2.□Therapeutic
 - 5.5.2.1.□Lung Cancer
 - 5.5.2.2.□Breast Cancer
 - 5.5.2.3.□Prostate Cancer
 - 5.5.2.4.□Colorectal Cancer
 - 5.5.2.5.□Others (Blood Cancer, Thyroid Cancer)
 - 5.6.□By End-user
 - 5.6.1.□Hospitals & Clinics
 - 5.6.2.□Academic & Research Institutions
 - 5.6.3.□Ambulatory Care Centers
 - 5.7.□By Region
 - 5.7.1.□Western Australia
 - 5.7.2.□Northern Territory
 - 5.7.3.□Queensland
 - 5.7.4.□South Australia
 - 5.7.5.□New South Wales
 - 5.7.6.□Victoria
 - 5.7.7.□Tasmania
 - 5.8.□By Company Market Share (%), 2022
- 6.□Market Mapping, 2022
- 1.1.□By Product Offered
 - 1.2.□By Technique
 - 1.3.□By Circulating Biomarker
 - 1.4.□By Application
 - 1.5.□By End-user
 - 1.6.□By Region
- 7.□Macro Environment and Industry Structure
- 7.1.□Supply Demand Analysis
 - 7.2.□Import Export Analysis
 - 7.3.□Value Chain Analysis
 - 7.4.□PESTEL Analysis
 - 7.4.1.□Political Factors
 - 7.4.2.□Economic System
 - 7.4.3.□Social Implications
 - 7.4.4.□Technological Advancements
 - 7.4.5.□Environmental Impacts

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.6. □ Legal Compliances and Regulatory Policies (Statutory Bodies Included)
 - 7.5. □ Porter's Five Forces Analysis
 - 7.5.1. □ Supplier Power
 - 7.5.2. □ Buyer Power
 - 7.5.3. □ Substitution Threat
 - 7.5.4. □ Threat from New Entrant
 - 7.5.5. □ Competitive Rivalry
 - 8. □ Market Dynamics
 - 8.1. □ Growth Drivers
 - 8.2. □ Growth Inhibitors (Challenges and Restraints)
 - 9. □ Key Players Landscape
 - 9.1. □ Competition Matrix of Top Five Market Leaders
 - 9.2. □ Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
 - 9.3. □ Mergers and Acquisitions/Joint Ventures (If Applicable)
 - 9.4. □ SWOT Analysis (For Five Market Players)
 - 9.5. □ Patent Analysis (If Applicable)
 - 10. □ Pricing Analysis
 - 11. □ Case Studies
 - 12. □ Key Players Outlook
 - 12.1. □ Medtronic plc
 - 12.1.1. □ Company Details
 - 12.1.2. □ Key Management Personnel
 - 12.1.3. □ Products & Services
 - 12.1.4. □ Key Market Focus & Geographical Presence
 - 12.1.5. □ Financials (As Reported)
 - 12.1.6. □ Recent Developments
 - 12.2. □ Becton, Dickinson, and Company
 - 12.3. □ Boston Scientific Corporation
 - 12.4. □ Roche Molecular Systems, Inc.
 - 12.5. □ Bio-Rad Laboratories, Inc.
 - 12.6. □ Beckman Coulter, Inc.
 - 12.7. □ Qiagen N.V.
 - 12.8. □ Thermo Electron Australia Pty Limited
 - 12.9. □ Illumina Australia Pty Ltd.
 - 12.10. □ Agilent Technologies Australia Pty Ltd
 - 12.11. □ Olympus Australia Pty Ltd
- *Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work
- 13. □ Strategic Recommendations
 - 14. □ About Us & Disclaimer

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Australia Minimally Invasive Biopsy Techniques Market Assessment, By Product Offered [Tests, Kits & Consumables, Instruments], By Technique [Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others], By Circulating Biomarker [Circulating Tumor Cells, Cell Free DNA, Circulating Tumor DNA, Extracellular Vesicles, Others], By Application [Clinical, Therapeutic], By End-user [Hospitals & Clinics, Academic & Research Institutions, Ambulatory Care Centers], By Region, Opportunities and Forecast, 2016-2030F

Market Report | 2024-04-19 | 105 pages | Market Xcel - Markets and Data

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|-----------------------------|-----------|
| | Single User License | \$3300.00 |
| | Muti-User/Corporate Licence | \$4500.00 |
| | Custom Research License | \$7000.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

| | | | |
|---------------|----------------------|-------------------------------|---|
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | <input type="text" value="2026-03-16"/> |
| | | Signature | <input type="text"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com